Patent intelligence · US
US 6878736
Histamine H3 receptor ligands
Histamine H3 receptor ligands
Patent details — US 6878736
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 12, 2005
- Expiration
- Apr 7, 2025
- Applicant
- The James Black Foundation Limited
- Claims
- 11
- CPC classes
- A61P, A61P1/04, A61P25/00, A61P25/20
Quick answer
US 6878736 (Histamine H3 receptor ligands) is held by The James Black Foundation Limited. Status: expired. Granted Apr 12, 2005. Expires Apr 7, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The James Black Foundation Limited
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61P, A61P1/04, A61P25/00, A61P25/20, A61P25/24, A61P43/00
More from The James Black Foundation Limited
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 6878736?
US 6878736 (Histamine H3 receptor ligands) is held by The James Black Foundation Limited. Status: expired. Granted Apr 12, 2005. Expires Apr 7, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6878736?
The James Black Foundation Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 6878736 expire?
Our index shows an expiration date of Apr 7, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.